| abstract |
The present invention relates to novel compounds of formula I having the properties of inhibitors of Bruton's tyrosine kinase (Btk): Embedded image Or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein V 1 is C or N; V 2 is C (R 2 ) or N; If V 1 is C, then V 2 is N; When V 1 is C, V 2 is С (R 2 ), or when V 1 is N, V 2 is С (R 2 ); Each n, k is independently 0, 1; Each R 2 , R 11 is independently H, D, Hal, CN, NR′R ″, C (O) NR′R ″, C 1 -C 6 alkoxy; R 3 is H, D, hydroxy, C (O) C 1 -C 6 alkyl, C (O) C 2 -C 6 alkenyl, C (O) C 2 -C 6 alkynyl, C 1 -C 6 alkyl ; R 4 is H, Hal, CN, CONR′R ″, hydroxy, C 1 -C 6 alkyl, C 1 -C 6 alkoxy; L is CH 2 , NH, O or a chemical bond; R 1 is (Each А 1 , А 2 , ３ 3 , ４ 4 is independently СН, N, СHal; Each of А 5 , ６ 6 , А 7 , ８ 8 , А 9 is independently С, СH or N; R 5 is H, CN, Hal, CONR′R ″, C 1 -C 6 alkyl, unsubstituted or substituted by one or more halogens; Each R ′ and R ″ is independently selected from the group comprising H, C 1 -C 6 alkyl, C 1 -C 6 cycloalkyl, aryl) Selected from the group of fragments comprising: R 6 is (Each R 7 , R 8 , R 9 , R 10 is independently vinyl, methylacetylenyl) Selected from the group of: Hal is Cl, Br, I, F), It relates to pharmaceutical compositions comprising said compounds and their use as medicaments for treating diseases and disorders. |